ArticlePloS one2025
Anti-inflammatory effect of bergamot leaves extract attenuates cardiac remodeling in obese rats by regulating the protein expression of the collagen/metalloproteinase axis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation is associated with the pathogenesis of obesity-related disorders, including cardiac remodeling. Bergamot is known for its promising anti-inflammatory effects. Thus, this study aimed to investigate the anti-inflammatory effect of bergamot leaves extract (BLE) in attenuating cardiac remodeling in obese rats through the regulation of protein expression of the collagen/metalloproteinase axis. Male Wistar rats were fed a control diet (C) or a high sugar-fat diet (HSF) for 20 weeks. After developing cardiac remodeling, the animals were again distributed into three groups to receive BLE (50 mg/kg/day) or placebo (water) via gavage for 10 weeks: C, HSF and HSF + BLE. The HSF group exhibited obesity (HSF 8.77 ± 2.64 vs C 3.09 ± 1.02, p = 0.007), dyslipidemia (HSF 94.4 ± 19.1 vs C 26.7 ± 5.2, p < 0.001), hypertension (HSF 141 ± 8 vs C 120 ± 4, p = 0.001), insulin resistance (HSF 6.91 ± 1.38 vs C 2.47 ± 1.01, p < 0.001), cardiac remodeling and dysfunction, cardiac inflammation, decreased metalloproteinase-2 (MMP-2) (HSF 0.43 ± 0.09 vs C 0.71 ± 0.07, p = 0.009) and increased type III collagen (HSF 1.32 ± 0.27 vs C 1.00 ± 0.18, p = 0.038). In contrast, BLE was effective in improving dyslipidemia (HSF + BLE 55.2 ± 9.7 vs HSF 94.4 ± 19.1, p < 0.001), insulin resistance (HSF + BLE 3.79 ± 0.76 vs HSF 6.91 ± 1.38, p < 0.001), cardiac remodeling and function, as well as inflammation, MMP-2 (HSF + BLE 0.84 ± 0.22 vs HSF 0.43 ± 0.09, p < 0.001) and type III collagen (HSF + BLE 0.68 ± 0.11 vs HSF 1.32 ± 0.27, p < 0.001) in the HSF group. Therefore, the anti-inflammatory effect of BLE improved cardiac remodeling in obese rats through the regulation of protein expression of the collagen/metalloproteinase axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.